Varicella and herpes zóster
Keywords:
zoster, varicella, post-herpetic neuralgiaAbstract
Varicella zoster virus infection is the most prevalent disease in the world, affecting 95% of the adult population. Its most aggressive manifestation is herpes zoster, which primarily affects adults and immunosuppressed patients. Treatment is effective with acyclovir and drug derivatives such as valaciclovir and famciclovir. New vaccines such as Zostavax and Shingrix, recently approved in Brazil, are important tools in preventing zoster and its main complication, post-herpetic neuralgia.
References
Alper BS, Lewis, PR. Treatment of posherpetic neuralgia: a systematic review of the literature. J. Fam. Pract. 2002; 51- 121-8.
Carter GT, Galer BS. Advances in the management of neurophatic pain. Phys. Med. Rehabil. Clin. N. Am. May/2001; 12(2)-447-59.
Cunningham AL et al. 2016. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 375:1019-32.
Davies SJ. A novel treatment of postherpetic neuralgia using peppermint oil. The Clin. J. Pain. May/June/2002; 18(3)-200-02.
Friesen KJ, Alessi-Severini S, Chateau D, Falk J, Bugden S 2016. The changing landscape of antiviral treatment of herpes zoster: a 17-year population-based cohort study. ClinicoEconomics and Outcomes Research: CEOR. 8:207-214.
Guidelines on the Treatment of Skin and Oral HIV–Associated Conditions in Children and Adults 2014. Geneva: World Health Organization.
Jeon YH 2015. Herpes Zoster and Postherpetic Neuralgia: Practical Consideration for Prevention and Treatment. Korean J Pain. 28(3):177-84.
Johnson RW, Alvarez-Pasquin MJ, Bijl M, Franco E, Gaillat J, Clara JG et al. 2015. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Therapeutic Advances in Vaccines, 3(4), 109–120.
Marin M, Yawn BP, Hales CM, Wollan PC, Bialek SR, Zhang J, Kurland MJ, Harpaz R 2015. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status. Hum Vaccin Immunother.;11(5):1157-64.
“Matrix é Aqui”. Ser Médico (Cremesp) Jul/Ago/Set/2009; n. 48. p. 14-15.
McCrary ML et al. Varicella Zoster Virus (CME). J. Am. Acad. Dermatology. July/1999; 41(1)-1-16.
Nagasako EM et al. Rash severity in herpes zoster: correlates and relationship to postherpetic neuralgia. June/2002; 46 (6)-834-9.
Oxman MN et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Eng. J. Med. Jun/2005; 352, 2271-84.
Préaud E, Uhart M, Böhm K, Aidelsburger P, Anger D, Bianic F, Largeron N 2015 Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany. Hum Vaccin Immunother.;11(4):884-96.
Rice G et al. Gabapentine in the treatment of postherpetic neuralgia. Pain. 2001; 94-215-24.
Rook A et al. Herpes-zoster. Textbook of dermatology. 4th edition. Blackwell Editions.1986; Vol.1. p. 680-85.
Sampaio S, Rivitti EA. Herpes-zoster. 3. ed. Dermatologia. Artes Médicas. 2007; 560-1.
Shuanglin H et al. Gene transfer of glutamic acid decarboxylase reduces neurophatic pain. Annals of Neurology. June/2005; 57(6) 914-18.
Teixeira MJ et al. Iontoforese de vincristina para o tratamento de neuralgia pós-herpética. Arq. Brasil. de Neuroc. 1993; (12)223-34.
Tseng HF, Liu A, Sy L, Marcy SM, Fireman B, Weintraub E et al. 2012 Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study. J Intern Med. 271(5):510-20.
